Diabetes and Hypertension

Nabil K Elnaggar

President of Jeddah Diabetes Club & Hypertension & Atherosclerosis Club, P.O Box 10153, Jeddah 21433, KSA

Abstract

The prevalence of hypertension is increasing worldwide, with an estimated 972 million adults with hypertension in 2000 that is predicted to grow to 1.56 billion by 2025, while diabetes worldwide prevalence is estimated as 382 million in 2012 projected to reach 592 billion in 2030. Diabetes mellitus and hypertension are interrelated diseases that strongly expose patients to increased risk of atherosclerotic cardiovascular and kidney disease. The prevalence of coexisting hypertension and diabetes appears to be increasing in industrialized nations because populations are aging and both hypertension and T2DM (type 2 diabetes mellitus) incidence increases with age. A number of possible reasons have been adduced for this coexistence and it is postulated that both diseases share common pathogenetic factors such as insulin resistance, aging, obesity, chronic subclinical inflammatory processes beside the use of thiazide diuretics in subjects initially with hypertension and the development of nephropathy in those initially with diabetes, especially type 1. Diabetes may also be associated with systolic hypertension secondary to atherosclerosis. In addition both conditions show familiar clustering, which makes it likely to be polygenic in origin. In Diabetics, increased plasma viscosity, stiffness of large arteries, increased production of oxidative radicals and excessive AGEs formation (Advanced Glycation End products) are relevant factors for the development of hypertension. Data from clinical trials emphasize the need for vigilant blood pressure control in patients with diabetes and hypertension. A target blood pressure goal < 140/90 mmHg is recommended by some guidelines while others still recommend more tight control of <130/80. Evidence shows that, to achieve the set goal, use of multiple-drug antihypertensive therapy is required. Agents should be used that have been shown to reduce cardiovascular risk, while not worsening concomitant conditions. It is appropriate that an agent that can block RAAS, such as an ACE inhibitor or an ARB should be the first choice in monotherapy and should be one of the partner drugs used in combination in hypertensive patients with diabetes or glucose intolerance.

Keywords: Hypertension; Diabetes; Cardiovascular diseases; Apolipoprotein; Glucose tolerance

Introduction

The prevalence of hypertension is increasing worldwide, with an estimated 972 million adults with hypertension in 2000 that is predicted to grow to 1.56 billion by 2025; while diabetes worldwide prevalence is estimated as 382 million in 2012 projected to reach 592 billion in 2030.

Diabetes mellitus and hypertension are interrelated diseases that strongly expose patients to highly increased risk of atherosclerotic cardiovascular and kidney disease. This association has been called the deadly duet in order to emphasize the increased cardiovascular risk when the two conditions co-exist. Hypertension affects approximately 70% of patients with diabetes and is approximately twice as common in persons with diabetes as in those without. The prevalence of coexisting hypertension and diabetes appears to be increasing in industrialized nations because populations are aging and both hypertension and T2DM (Type 2 Diabetes Mellitus) incidence increases with age, beside the effect of current improvement in health care.

Hypertensive people are 2.5 times more likely to develop diabetes mellitus within five years [1]. In the Hong Kong Cardiovascular Risk Factor Prevalence Study, only 42% of people with diabetes had normal blood pressure and only 56% of people with hypertension had normal glucose tolerance [2]. In US population, hypertension occurs in approximately 30% of patients with type 1 diabetes and in 50% to 80% of patients with type 2 diabetes [3].

Hypertensive disease has been implicated in 4.4% of deaths coded to diabetes, and diabetes was involved in 10% of deaths coded to hypertensive disease. Indeed, an estimated 35% to 75% of diabetic cardiovascular and renal complications can be attributed to hypertension. The presence of hypertension causes a 7.2-fold increase and a 37-fold increase in mortality in diabetic patients and in diabetic nephropathy respectively.

Diabetes mellitus is an independent risk factor for coronary artery disease, and the risk is markedly increased when hypertension is present. Hypertension also contributes to diabetic retinopathy, which is the leading cause of newly diagnosed blindness. Also the cerebrovascular arterial bed had been demonstrated to be largely affected by the duet; as it was found an increase in intima-media thickness in diabetics of 0.005 mm with every additional year of age, carotid damage occurred in 23% of the diabetics, 12% of the hypertensive patients and 3.4% of the controls [4].

There are particular subpopulations in which the coexistence of hypertension and diabetes can pose serious risks. Pregnant women with diabetes and hypertension are at risk for pre-eclampsia. Children with type 1 diabetes and hypertension are particularly vulnerable to...
early end-organ disease. The increase in incidence of childhood type 2 diabetes is worrisome, as cardiovascular risk factors early in life can cause accelerated atherosclerosis in early life.

For all these data both hypertension and diabetes should be diagnosed early and treated aggressively to prevent associated microvascular and macrovascular morbidity and mortality.

The Pathophysiology

A number of possible reasons have been adduced for this coexistence; it was postulated that both diseases share common pathogenetic factors such as insulin resistance, aging, obesity, chronic subclinical inflammatory processes and use of thiazide diuretics in subjects initially with hypertension and the development of nephropathy in those initially with diabetes, especially type 1. Diabetes may also be associated with systolic hypertension secondary to atherosclerosis.

In addition the two disorders show familiar clustering, which makes it likely to be polygenic in origin. Genetic variants in the gene encoding angiotensinogen, adrenomedullin, apolipoprotein, and α-adducin have been reported to be associated with common conditions such as diabetes, hypertension, dysglycemia, or metabolic syndrome [5-8].

The insulin resistance hypothesis is gaining more acceptance as a common aetiological factor for both diseases [9]; “the common soil hypothesis” is a term coined to point out that the two diseases originate from the same soil rooting from insulin resistance [10]. Insulin resistance is associated with impaired insulin signalling, impaired fibrinolysis, and inflammation. A high insulin level was assumed to cause hypertension through its role in the development of increased arterial stiffness, and increased vascular volume by salt and water retention, and finally, by stimulating the sympathetic nervous system, which causes a state of persistent vasoconstriction, ultimately leading to hypertension [11,12]. Insulin resistance arises due to various genetic, acquired, and environmental factors leading to visceral obesity. Increased rennin-angiotensin-aldosterone system (RAAS) activity may also cause insulin resistance via the stimulation of Ang II type 1 receptors, which trigger increased production of reactive oxygen species (ROS) in adipocytes, skeletal muscle, and cardiovascular tissue of obese individuals [13-15].

It has been demonstrated in multiple studies that plasma insulin response to a glucose challenge in a glucose tolerance test was twice as high in individuals with hypertension and obesity as in the control subjects, indicating that these individuals were clearly insulin resistant. Systolic blood pressure was directly correlated to the two hours plasma insulin level. There was a linear relationship between serum insulin level and the magnitude of blood pressure elevation [16,17].

Another important factor is the elevation of plasma viscosity which is a feature of diabetic blood, resulting in greater flow resistance and a high incidence of circulatory complications related to the corresponding increase in fibrinogen level [18-21].

An increasing bulk of evidence suggests that free radical over generation may be considered the key in the development of insulin resistance, diabetes and cardiovascular disease [22]. It has been demonstrated that insulin resistance in humans is associated with reduced intracellular antioxidant defence [23], and that diabetic subjects prone to complications may have a defective intracellular antioxidant response [24,25], configuring what is called genetic predisposition to diabetes, as well as liability to its late complications, which might be based on this deficient ROS-scavenging ability in B-cells and/or in target tissues such as endothelium.

The role of the stiff large arteries in diabetics and their contribution to hypertension development have been largely emphasized. Both the hypertensive and the diabetic patients have an increased stiffness of their large arteries. Even in the early stage of hypertension, there is evidence for reduced large artery compliance [26]. Changes of arterial stiffness in diabetes have been reviewed by Stehouwer and Ferreira [27]. Recent studies investigating the association between both type 1 and type 2 diabetes and arterial stiffness have consistently shown that these patients have stiffer arteries than non-diabetic subjects. In both groups of patients, arterial stiffness precedes clinical cardiovascular disease. In type 1 diabetes, increased pulse pressure, a common marker of arterial stiffness was detected in patients in their early thirties. In type 2 diabetes, macrovascular changes also begin at the prediabetic stage [27]. These data support the concept that diabetes, in part, has a vascular etiology.

Several mechanisms have been implicated in the diabetes-associated increase in arterial stiffness. Tropeano AI, et al. [28] showed that glyceria was the major determinant of arterial stiffness in diabetic patients. Hyperglycemia causes endothelial dysfunction which in turn causes arterial stiffness [29,30]. An alternative or additional mechanism of large artery stiffness in diabetes is the AGE-related stiffening of collagen in the vessel wall through provoking endothelial dysfunction. Evidence for such a mechanism has been derived from studies with drugs that interfere with the formation of these glycosylated vessel wall molecules [31]. Also, it was found that in both diabetes and hypertension there was extensive remodelling and narrowing of small vessels that was attributed to inward eutrophic remodelling without net cell growth induced by chronic vasocostriction [32-34]. In diabetic patients, a clear increase in the media cross-sectional area in small vessels has been observed, suggesting the presence of hypertrophic remodelling. This hypertrophy may be related to a cellular growth response to increased levels of insulin or insulin-like growth factor 1 [35,36].

Management

As previously emphasized, diabetics and hypertensive patients should be identified early and treated promptly to achieve the target goals of control of both conditions. Critical evidence from several large scale studies indicated that tight control of diabetes and hypertension can effectively and robustly decrease the risk of the associated high mortality and morbidity or even delay the complication development. It has been estimated that blood pressure reduction of 2 mmHg decreases the risk of cardiovascular events by 7-10% [37]. Drug therapy is required in the management of these patients, but lifestyle modification and weight management are key components to reduce glycemia and control blood pressure.

The UK Prospective Diabetes Study (UKPDS) showed that blood pressure control helps to prevent cardiovascular complications in patients with type 2 diabetes; each 10 mmHg decrease in mean systolic blood pressure was associated with 12% reduction in the risk for any complication related to diabetes, 15% reduction in deaths related to diabetes, 11% reduction in myocardial infarction and 13% reduction in microvascular complications and there was no threshold of blood pressure where risk was not observed. In the same study, it has been
shown that tight control of BP was even more protective than glucose
tight control as long as macrovascular events were concerned [38].

The HOPE study [39] (The Heart Outcomes Prevention Evaluation
study) showed that inhibition of angiotensin-converting enzyme in
patients with type 2 diabetes significantly reduces the risk of vascular
complications.

Despite the availability of numerous effective antihypertensive
medications, many diabetic-hypertensive adults remain uncontrolled
for various reasons, including inadequate treatment or noncompliance. Among hypertensive patients receiving treatment, the estimated proportion of patients with blood pressure uncontrolled to
<140/90 mm Hg ranges from 47% to 84% in Europe and North
America.

Furthermore, a subset of patients who adhere, continue to be
uncontrolled, The HOT (Hypertension Optimal Treatment study) [40]
showed that diabetics will need 2-3 drugs to control their BP.

The Systolic Hypertension in the Elderly Program (SHEP) [41] and
other studies like HDHP [42], Syst-Euro [43], HOT [40], normotensive
ABCD [44], and HOPE [39] provide firm evidence that even small BP
reductions translate to significant decrease in both micro and
macrovascular complications in persons with type 2 diabetes. The
ADVANCE study [45] showed that intensive control of BP resulted in
reduction in composite micro and macrovascular complications by
9%, coronary events by 14% and renal events by 21%.

In diabetics, a target blood pressure goal of <130/80 was previously
recommended by most of the guideline-developing authorities
especially in the case of nephropathic diabetics which is a very
common early complication among them; a new recommended target
of <140/90 mmHg which is both reasonable and safe to achieve has
been recommended by a number of recent guidelines including the
2013 European Society of Hypertension/European Society of
Cardiology, and the JNC 8 guidelines. The 2013 American Diabetes
Association guidelines recommend a target of <140/80 and <130/80
in some diabetic populations such as younger patients if it can be
achieved without undue treatment burden, moreover, the 2014
American Society of Hypertension/International Society of
Hypertension guidelines recommends the old target of <130/80 for
diabetics as stated “lower targets than 140/90 may be appropriate in
some populations such as African Americans, the elderly, the LV
hypertrophy patients, those with systolic/diastolic dysfunction,
diabetes mellitus or those with chronic kidney disease”. However, the
Canadian hypertension 2013 guidelines, and NICE (National Institutes
of Clinical excellence) 2014 guidelines still recommends a target of
<130/80 especially if diabetes is present with nephropathy.

In fact, although a number of studies (UKPDS and Hypertension
Optimal Treatment (HOT), and normotensive ABCD trial) have
demonstrated the improved outcomes in patients assigned to lower
blood pressure targets, which goes in harmony with the results of The
Advance Collaborative Group study demonstrating the benefit of an
angiotensin-converting enzyme (ACE) inhibitor and indapamide in a
fixed combination, and strongly suggesting that the blood pressure
goal (<130/80 mmHg) was beneficial; The ACCORD trial was unable
to find a significant reduction in incidence of major CV events in
patients with diabetes whose SBP was lowered to an average of
119mmHg compared with patients whose SBP remained at an average
of 135mmHg. Other trials of rigorous control like ACTIVE, INVEST
(DM) [46], ONTARGET [47], NAVIGATOR [48], TRANSCEND
[49], AND RAODMAP [50], demonstrated no extra benefit in high
risk patients.

A conflicting situation arises when comparing previous epidemiological analyses showing that blood pressure ≥ 120/70 mmHg is
associated with increased cardiovascular event rates and mortality in
patients with diabetes and the recent data of outcome results of
intervention to achieve blood pressure <120/70 demonstrating increased risk of CV risk. These results had revived the “J-Curve”
concept relating the effect of tight reduction below 120/70 on coronary
flow leading to increased CHD risk. The approach and type of
medications used in the intervention may have a role in the increased
risk found in these studies.

Based on recent outcome studies, the ESC/ESH guidelines 2013
[51], state that “Whether the presence of microvascular disease (renal,
ocular, or neural) in diabetes requires treatment initiation and targets
of lower BP values is also unclear. Although, micro albuminuria can be
delayed or reduced by hypertension treatment; trials in diabetic
populations, including normotensives and hypertensive, have been
unable to demonstrate consistently that proteinuria reduction is also
accompanied by a reduction in hard CV outcomes”.

It became crystal clear that in order to achieve the set goal of
<140/90 mmHg, use of multiple-drug antihypertensive therapy is
required. Agents should be used on an evidence base proof for their
ability to reduce the cardiovascular risk, while not worsening
concomitant conditions, e.g. new onset diabetes or abnormal lipids or
even precipitate new disease. The European Society of Hypertension
guidelines in 2013 [51] stated that “A meta-analysis of more than 40
studies has shown that combining two agents from any two classes of
antihypertensive drugs increases the BP reduction much more than
increasing the dose of one agent. The advantage of initiating with
combination therapy is a prompter response in a larger number of
patients (potentially beneficial in high-risk patients), a greater
probability of achieving the target BP in patients with higher BP
values, and a lower probability of discouraging patient adherence
with many treatment changes. Indeed, a recent survey has shown that
patients receiving combination therapy have a lower drop-out rate
than patients given any monotherapy. A further advantage is that there
are physiological and pharmacological synergies between different
classes of agents that may not only justify a greater BP reduction but
also cause fewer side-effects and may provide larger benefits than
those offered by a single agent.”

Because of a greater effect of RAAS (Renin-Angiotensin-
Aldosterone System) blockers on urinary protein excretion, it appears
reasonable to have either an ACE (Angiotensin converting enzyme)
inhibitor or an ARB (angiotensin receptor blockers) in the
combination based on their proven efficacy and safety trials. Clinical
trials with diuretics, beta blockers, ACE inhibitors, ARBs and calcium-
channel antagonists have all demonstrated benefit in the treatment of
hypertension in type 1 diabetes mellitus, as well as type 2 diabetes
mellitus. This benefit is related to the degree of blood-pressure
lowering. A sub-analysis of the ACCOMPLISH [52] trial has reported
that the association of an ACE inhibitor with a calcium antagonist,
rather than a thiazide diuretic, is more effective in preventing doubling
serum creatinine and ESRD, though less effective in preventing
proteinuria.
Effects of Drugs on Both Diseases

**Effects of anti-hypertensives on diabetes**

All the major classes of antihypertensive can be used in diabetics, but the thiazide diuretics and beta-blockers have metabolic side-effects such as increasing insulin resistance or direct diabetogenesis, which make them less appropriate as first line agents [53]. RAAS blockers and calcium channel antagonists are suitable as first line antihypertensive in diabetics. The calcium channel blockers (CCBs) and RAAS blockers have better metabolic profiles and the latter reduce insulin resistance and may improve glycemia in diabetics and patients with the metabolic syndrome. RAAS blockers may also have a renal protective effect in incipient nephropathy [54].

The use of CCBs was not significantly associated with incident diabetes compared to other antihypertensive agents: the association with diabetes was lowest for ACEIs and ARBs, followed by CCBs, β blockers, and diuretics [55]. Further, it was surprisingly discovered recently that calcium channel blockers can even prevent diabetes and increase B cell survival. The mechanisms behind that is thought to be through the inhibition of the expression of a protein called TXNIP (Thioredoxin Interacting Protein) in human islets and that orally administered verapamil resulted in reduction of TXNIP expression and B-cell apoptosis, enhanced endogenous insulin levels, and rescued mice from STZ-induced diabetes. Verapamil also promoted B-cell survival and improved glucose homeostasis and insulin sensitivity in ob/ob mice [56].

**Effects of anti-diabetics on blood pressure**

Table 1 shows the currently approved anti-diabetic agents, their cellular mechanisms and physiologic actions. The mechanisms mentioned involve their anti-diabetic actions which can be related to side actions where changes of blood pressure subsequently occurs, such as the case of insulin and SGLT-2 inhibitors; insulin causes salt and water retention, increases body weight and it causes growth of tissues as an anabolic hormone, on the contrary leading to elevations in blood pressure, on the contrary, SGLT-2 inhibitors causes osmotic diuresis leading to blood pressure reduction [57-60]. Other medications, such as GLP-1 agonists and DPP-4 inhibitors have been demonstrated to exert their effects directly through the activation of their receptors on the cardiac and vascular tissues or centrally positioned receptors. Table 2 demonstrates the effects of the different anti-diabetics on blood pressure [61-63].

<table>
<thead>
<tr>
<th>Oral Antidiabetic Agents</th>
<th>Class</th>
<th>Biguanides</th>
<th>Sulphonylurea</th>
<th>Dpp-4 Inhibitors</th>
<th>TZDS</th>
<th>Alpha Glucosidase Inhibitors</th>
<th>Sglt2 Inhibitors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>Metformin</td>
<td>Glibenclamide</td>
<td>Glimepride</td>
<td>Sitagliptin</td>
<td>Pioglitazone</td>
<td>Acarbose</td>
<td>Canagliflozin</td>
</tr>
<tr>
<td>Cellular Mechanism</td>
<td>activates AMP kinase</td>
<td>closes k+ channels on b cell</td>
<td>Inhibits glp-1 degrading enzyme</td>
<td>activates nuclear ppar receptors</td>
<td>inhibits intestinal alpha glucosidase</td>
<td>inhibits sod/glucose transporter 2</td>
<td></td>
</tr>
<tr>
<td>Main Actions</td>
<td>decrease hepatic glucose output</td>
<td>increases insulin secretion</td>
<td>increases insulin decreases glucagon</td>
<td>increase insulin sensitivity</td>
<td>slow glucose absorption</td>
<td>inhibits glucose renal reabsorption</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Injectable Antidiabetic Agents</th>
<th>Class</th>
<th>Insulin</th>
<th>Glp-i Agonists</th>
<th>Amylin Mimetics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name</td>
<td>various premixed short/long acting</td>
<td>Exenatide</td>
<td>Pramlintide</td>
<td></td>
</tr>
<tr>
<td>Cellular Mechanism</td>
<td>activates insulin receptors</td>
<td>Activates GLP-1 receptors</td>
<td>mimics the naturally secreted amylin which is deficient in diabetics</td>
<td></td>
</tr>
<tr>
<td>Main Actions</td>
<td>increase glucose disposal decrease hepatic glucose production</td>
<td>increase insulin secretion decrease glucagon secretion increases satiety slows gastric emptying</td>
<td>slow gastric emptying regulate postprandial glucagon increase satiety</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: The available anti-diabetic agents, their cellular mechanisms and main actions action
### Effects of Antidiabetic Drugs on Blood Pressure

<table>
<thead>
<tr>
<th>Drug Class</th>
<th>Effect on Blood Pressure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulins</td>
<td>Small increases</td>
</tr>
<tr>
<td>Biguanides (metformin)</td>
<td>No effect</td>
</tr>
<tr>
<td>Sulphonylureas and Glinides</td>
<td>No effect</td>
</tr>
<tr>
<td>DPP-4 inhibitors</td>
<td>Small reductions</td>
</tr>
<tr>
<td>GLP-1 agonists</td>
<td>Reduce blood pressure</td>
</tr>
<tr>
<td>SGLT-2 inhibitors</td>
<td>Reduce blood pressure</td>
</tr>
<tr>
<td>Amylin mimetics</td>
<td>No effect</td>
</tr>
</tbody>
</table>

**Table 2:** The effect of the different anti-diabetic drugs on blood pressure

In summary, only insulin can raise blood pressure while other agents are either neutral or of limited power for reduction of blood pressure.

### References


